首页> 外文期刊>Journal of enzyme inhibition and medicinal chemistry. >Synthesis and inhibition potency of novel ureido benzenesulfonamides incorporating GABA as tumor-associated carbonic anhydrase IX and XII inhibitors
【24h】

Synthesis and inhibition potency of novel ureido benzenesulfonamides incorporating GABA as tumor-associated carbonic anhydrase IX and XII inhibitors

机译:新型脲苯磺酰胺的合成与抑制效力,将GABA作为肿瘤相关的碳酸酐酶IX和XII抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

New ureido benzenesulfonamides incorporating a GABA moiety as a linker between the ureido and the sulfonamide functionalities were synthesized and their inhibition potency determined against both the predominant cytosolic (hCA I and II) and the transmembrane tumor-associated (hCA IX and XII) isoforms of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1). The majority of these compounds were medium potency inhibitors of the cytosolic isoform hCA I and effective hCA II inhibitors, whereas they showed strong inhibition of the two transmembrane tumor-associated isoforms hCA IX and XII, with K(I)s in nanomolar range. Only one derivative had a good selectivity for inhibition of the tumor-associated hCA IX target isoform over the cytosolic and physiologically dominant off-target hCA I and II, being thus a potential tool to develop new anticancer agents.
机译:结合了将GABA部分掺入Ureido和磺酰胺官能团之间的接头的新脲苯磺酰胺,并针对主要细胞溶质(HCA I和II)和跨膜肿瘤相关(HCA IX和XII)的抑制效力。 金属酶碳酸酐酶(CA,EC 4.2.1.1)。 这些化合物中的大部分是细胞溶质同种型HCA I和有效HCA II抑制剂的中等效力抑制剂,而它们表现出强烈抑制两种跨膜肿瘤相关的同种型HCA IX和XII,其中K(i)载于纳米摩尔范围。 因此,只有一种衍生物具有良好的选择性,可抑制肿瘤相关的HCA IX靶同种型在细胞溶质和生理学上显性的脱靶HCA I和II上,因此是开发新的抗癌剂的潜在工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号